Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Myeloma Patients May Be Able To Use Carfilzomib Before FDA Approval…

Home/Research, Supplements/Drugs/Myeloma Patients May Be Able To Use Carfilzomib Before FDA Approval…

Myeloma Patients May Be Able To Use Carfilzomib Before FDA Approval…

Yesterday I ran a post, sharing the good news that Onyx Pharmaceuticals has submitted their Official FDA application for carfilzomib.

Multiple Myeloma patients who are running out of treatment options may be eligible to use carfilzomib, even before it is approved.  Here is information about the program:

The Carfilzomib Myeloma Access Program (C-MAP)

Providing Access to Individuals with Relapsed and Refractory Multiple Myeloma

Onyx Pharmaceuticals and the Multiple Myeloma Research Foundation (MMRF) have established the Carfilzomib Myeloma Access Program (C-MAP), an expanded access program that makes carfilzomib available to eligible patients in the United States with relapsed and refractory multiple myeloma. Under an Expanded Access Program, the U.S. Food and Drug Administration (FDA) allows seriously ill patients who lack any treatment options to try a promising drug that is still under development.

Interested patients should talk to their physician or call Onyx Medical Information to learn if they are eligible for the trial:

Onyx Medical Information
Toll Free: 1-877-ONYX-1-2-1 (1-877-669-9121)
International: 1-650-266-2434
Email: medinfo@onyx-pharm.com

Here is a direct link to the Onyx/carfilzomib Access Program site for more information:

CARFILZOMIB MYELOMA ACCESS PROGRAM

Glad to help.  Feel good and keep smiling!  Pat